Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC)R Frazer, J M McGrane, A Challapalli, et al.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Human Molecular Genetics|December 6, 2011
Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIPXiaobo Zhou, Rebecca M Baron, Megan Hardin, et al.
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Pageof 7